LeMaitre VascularLMAT
About: LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Employees: 630
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
75% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 24
27% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 95
24% more call options, than puts
Call options by funds: $332K | Put options by funds: $267K
5% more funds holding
Funds holding: 288 [Q3] → 303 (+15) [Q4]
1.26% more ownership
Funds ownership: 92.92% [Q3] → 94.18% (+1.26%) [Q4]
1% more capital invested
Capital invested by funds: $1.94B [Q3] → $1.95B (+$11.6M) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Lake Street Brooks O'Neil 25% 1-year accuracy 4 / 16 met price target | 30%upside $110 | Buy Maintained | 28 Feb 2025 |
Citizens Capital Markets Daniel Stauder 9% 1-year accuracy 1 / 11 met price target | 30%upside $110 | Buy Maintained | 28 Feb 2025 |
Wells Fargo Nathan Treybeck 0% 1-year accuracy 0 / 4 met price target | 12%upside $95 | Equal-Weight Initiated | 13 Feb 2025 |
Financial journalist opinion
Based on 7 articles about LMAT published over the past 30 days
